The blood–brain barrier (BBB) restricts the transport of potential therapeutic moieties to the
brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the …

The brain is in many ways an immunologically and pharmacologically privileged site. The
blood–brain barrier (BBB) of the cerebrovascular endothelium and its participation in the …

Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with
Gliadel wafers (GW) in adult patients with glioblastoma multiforme (GBM) at first recurrence …

Convection-enhanced delivery (CED) is a promising technique that generates a pressure
gradient at the tip of an infusion catheter to deliver therapeutics directly through the …

Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor
prognosis. Attempts to develop targeted therapies have been hindered because the blood …

The preeminent treatments for neurodegenerative disease are often unavailable due to the
poor accessibility of therapeutic drugs. Moreover, the blood–brain barrier (BBB) effectively …

Primary brain tumors have a significant infiltrative capacity as their reappearance after
resection usually occurs within 2cm of the tumor margin. Local delivery method such as …

The brain is highly accessible for nutrients and oxygen, however delivery of drugs to
malignant brain tumors is a very challenging task. Convection-enhanced delivery (CED) has …

Effective gene delivery to the central nervous system (CNS) is vital for development of novel
gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have …

Many studies have demonstrated that adeno-associated virus serotype 9 (AAV9) transduces
astrocytes and neurons when infused into rat or nonhuman primate (NHP) brain. We …